Cargando…
Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis
BACKGROUND: To identify high-risk patients and provide pharmacological treatment is one of the effective approaches in prevention of osteoporotic fractures. This study investigated the effect of 12-month Alendronate treatment on bone mineral density (BMD) and bone turnover biochemical markers in pos...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885425/ https://www.ncbi.nlm.nih.gov/pubmed/17511887 http://dx.doi.org/10.1186/1749-799X-2-9 |
_version_ | 1782133622978904064 |
---|---|
author | Qin, Ling Choy, Wingyee Au, Szeki Fan, Musei Leung, Pingchung |
author_facet | Qin, Ling Choy, Wingyee Au, Szeki Fan, Musei Leung, Pingchung |
author_sort | Qin, Ling |
collection | PubMed |
description | BACKGROUND: To identify high-risk patients and provide pharmacological treatment is one of the effective approaches in prevention of osteoporotic fractures. This study investigated the effect of 12-month Alendronate treatment on bone mineral density (BMD) and bone turnover biochemical markers in postmenopausal women with one or more non-traumatic fractures, i.e. patients with established osteoporosis. METHODS: A total of 118 Hong Kong postmenopausal Chinese women aged 50 to 75 with low-energy fracture at distal radius (Colles' fracture) were recruited for BMD measurement at lumbar spine and non-dominant hip using Dual-Energy X-ray Absorptiometry (DXA). 47 women with BMD T-score below -2 SD at either side were identified as patients with established osteoporosis and then randomized into Alendronate group (n = 22) and placebo control group (n = 25) for BMD measurement at spine and hip using DXA and distal radius of the non-fracture side by peripheral quantitative computed tomography (pQCT), and bone turnover markers, including bone forming alkaline phosphatase (BALP) and bone resorbing urinary Deoxypyridinoline (DPD). All measurements were repeated at 6 and 12 months. RESULTS: Alendronate treatment significantly increased BMD, more in weight-bearing skeletons (5.1% at spine and 2.5% at hip) than in non-weight bearing skeleton (0.9% at distal radius) after 12 months treatment. Spine T-score was significant improved in Alendronate group (p < 0.01) (from -2.2 to -1.9) but not in control placebo group. The Alendronate treatment effect was explained by significant suppression of bone turnover. CONCLUSION: 12 months Alendronate treatment was effective to increase BMD at both axial and appendicular skeletons in postmenopausal women with established osteoporosis. |
format | Text |
id | pubmed-1885425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-18854252007-06-01 Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis Qin, Ling Choy, Wingyee Au, Szeki Fan, Musei Leung, Pingchung J Orthop Surg Research Article BACKGROUND: To identify high-risk patients and provide pharmacological treatment is one of the effective approaches in prevention of osteoporotic fractures. This study investigated the effect of 12-month Alendronate treatment on bone mineral density (BMD) and bone turnover biochemical markers in postmenopausal women with one or more non-traumatic fractures, i.e. patients with established osteoporosis. METHODS: A total of 118 Hong Kong postmenopausal Chinese women aged 50 to 75 with low-energy fracture at distal radius (Colles' fracture) were recruited for BMD measurement at lumbar spine and non-dominant hip using Dual-Energy X-ray Absorptiometry (DXA). 47 women with BMD T-score below -2 SD at either side were identified as patients with established osteoporosis and then randomized into Alendronate group (n = 22) and placebo control group (n = 25) for BMD measurement at spine and hip using DXA and distal radius of the non-fracture side by peripheral quantitative computed tomography (pQCT), and bone turnover markers, including bone forming alkaline phosphatase (BALP) and bone resorbing urinary Deoxypyridinoline (DPD). All measurements were repeated at 6 and 12 months. RESULTS: Alendronate treatment significantly increased BMD, more in weight-bearing skeletons (5.1% at spine and 2.5% at hip) than in non-weight bearing skeleton (0.9% at distal radius) after 12 months treatment. Spine T-score was significant improved in Alendronate group (p < 0.01) (from -2.2 to -1.9) but not in control placebo group. The Alendronate treatment effect was explained by significant suppression of bone turnover. CONCLUSION: 12 months Alendronate treatment was effective to increase BMD at both axial and appendicular skeletons in postmenopausal women with established osteoporosis. BioMed Central 2007-05-21 /pmc/articles/PMC1885425/ /pubmed/17511887 http://dx.doi.org/10.1186/1749-799X-2-9 Text en Copyright © 2007 Qin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Qin, Ling Choy, Wingyee Au, Szeki Fan, Musei Leung, Pingchung Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title | Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title_full | Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title_fullStr | Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title_full_unstemmed | Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title_short | Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis |
title_sort | alendronate increases bmd at appendicular and axial skeletons in patients with established osteoporosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885425/ https://www.ncbi.nlm.nih.gov/pubmed/17511887 http://dx.doi.org/10.1186/1749-799X-2-9 |
work_keys_str_mv | AT qinling alendronateincreasesbmdatappendicularandaxialskeletonsinpatientswithestablishedosteoporosis AT choywingyee alendronateincreasesbmdatappendicularandaxialskeletonsinpatientswithestablishedosteoporosis AT auszeki alendronateincreasesbmdatappendicularandaxialskeletonsinpatientswithestablishedosteoporosis AT fanmusei alendronateincreasesbmdatappendicularandaxialskeletonsinpatientswithestablishedosteoporosis AT leungpingchung alendronateincreasesbmdatappendicularandaxialskeletonsinpatientswithestablishedosteoporosis |